Related Experiment Video

Updated: Jul 11, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

[Promising new treatment options for metastatic androgen-independent prostate cancer]

W Tan1

  • 1Genitourinary Oncology, Hematology, Oncology Mayo Clinic, Jacksonville, Florida 32224, USA. tan.winston@mayo.edu

Actas Urologicas Espanolas
|September 28, 2007
PubMed
Abstract

Insights

Recent advances in androgen independent prostate cancer (AIPC) treatment show docetaxel chemotherapy improves survival. However, further research is needed for less toxic options and longer progression-free survival in AIPC patients.

Area of Science:

  • Oncology
  • Urology

Background:

  • Androgen independent prostate cancer (AIPC) remains a significant clinical challenge.
  • Current treatments offer limited long-term efficacy.

Purpose of the Study:

  • To review recent advancements in AIPC treatment.
  • To identify novel therapeutic strategies and their clinical impact.

Main Methods:

  • Literature review of Medline/PubMed.
  • Inclusion of Phase II, III trials, and meeting abstracts.
  • Keywords: AIPC, hormone refractory prostate cancer, novel treatments.

Main Results:

  • Docetaxel-based chemotherapy (e.g., docetaxel/prednisone) demonstrated improved overall survival compared to mitoxantrone/prednisone.
  • Satraplatin showed a modest progression-free survival benefit in the second-line setting.
  • Relapse-free survival remains short for many responders.

Conclusions:

  • Docetaxel chemotherapy offers a survival benefit for AIPC patients.
  • There is a critical need for novel, less toxic agents with superior survival benefits.
  • Further research is essential to improve outcomes for advanced prostate cancer.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...